Hormone Insight

This week on Hormone Insight: the fallout from the ADA 2026 Scientific Sessions, where retatrutide — a triple GIP/GLP-1/glucagon agonist — delivered nearly 2 points of A1C and about 15% weight loss in type 2 diabetes (TRANSCEND-T2D-1). Plus CagriSema vs semaglutide head-to-head, finerenone in chronic kidney disease without diabetes, the new ADA/EASD type 1 diabetes consensus, and a Hormone Classic...

This week on This Week in Diabetes & Endocrinology, from Hormone Insight: the first large phase 3 trial of an oral GLP-1, orforglipron, in adults with type 2 diabetes and obesity (ATTAIN-2, Lancet). The headline is not the size of the weight loss. It is the word oral. Also this week: - A 112,000-patient ACP network meta-analysis that keeps semaglutide and  tirzepatide on top for both weight loss a...

Oral Ozempic Launch, Semaglutide for Alcohol Use Disorder (Lancet RCT), and Canada’s First Generic Semaglutide | Week Ending May 8, 2026 This short Week in Diabetes and Endocrinology update covers three key developments for the week ending May 8, 2026: the nationwide U.S. launch of Oral Ozempic (rebranded/reformulated oral semaglutide tablets in 1.5, 4, and 9 mg with smaller pill size, same effica...

This episode reviews key diabetes/endocrinology updates for the week ending May 1, 2026: FDA clearance of Tandem Control-IQ Plus automated insulin delivery for pregnancy in type 1 diabetes supported by the CIRCUIT trial showing improved pregnancy-specific time-in-range; a US cost-effectiveness analysis in type 2 diabetes finding tirzepatide 10 mg and 15 mg cost-effective vs semaglutide 2 mg (ICERs...

The Week in Diabetes & Endocrinology — Episode 004 | April 24, 2026 From Hormone Insight (hormoneinsight.com) Six stories this week that endocrinologists, diabetologists, and internists need to know. TIMESTAMPS: 0:00 — Introduction & This Week's Stories 1:15 — Tzield (Teplizumab) FDA Expanded to Age 1+ for Stage 2 Type 1 Diabetes 5:30 — AACE 2026 Annual Meeting in Las Vegas: What's Worth Watching...

The Week in Diabetes & Endocrinology — Episode 003 | April 17, 2026 From Hormone Insight (hormoneinsight.com) Six stories this week that endocrinologists, diabetologists, and internists need to know. TIMESTAMPS: 0:00 — Introduction & This Week's Stories 1:15 — Automated Insulin Delivery in Type 2 Diabetes: A Landmark Trial Worth Unpacking 5:30 — Enlicitide: The First Oral PCSK9 Inhibitor (CORALree...

The Week in Diabetes & Endocrinology — Episode 002 | April 10, 2026 From Hormone Insight (hormoneinsight.com) Six stories this week that endocrinologists, diabetologists, and internists need to know. TIMESTAMPS: 0:00 — Introduction & This Week's Stories 1:30 — EZ-PAVE: LDL Under 55 Beats Under 70 in ASCVD (NEJM) 7:00 — CMS BALANCE Model: Medicare Covers GLP-1 for Obesity 11:00 — GZR4: Second Once-...

The Week in Diabetes & Endocrinology — Episode 001 | April 3, 2026 From Hormone Insight (hormoneinsight.com) Six stories this week that endocrinologists, diabetologists, and internists need to know. TIMESTAMPS: 0:00 — Introduction & This Week's Stories 1:30 — Orforglipron (Foundayo) FDA Approval: The Oral GLP-1 Pill — Access-Changer, Not Game-Changer 7:00 — Semaglutide 7.2 mg (Wegovy HD): 21% Weig...

In this episode of Hormone Insight, we examine a 2024 post hoc analysis published in Diabetes Care. 

Exploring Semaglutide: Dual Action Therapy for Obesity and Heart Failure In this episode of Hormone Insights, we delve into a 2024 study from the New England Journal of Medicine that examines the effects of semaglutide in obese patients with heart failure, preserved ejection fraction, and type 2 diabetes.  For full paper, click here Visit HormoneInsight

In this episode of Hormone Insight, we delve into a major study published in The Lancet Diabetes and Endocrinology that compared the effects of semaglutide and canagliflozin as add-ons to metformin in diabetes treatment.  For more: Semaglutide vs Canagliflozin for Type 2 Diabetes To read the original paper

In patients with heart failure with preserved ejection fraction (HFpEF) and obesity,  tirzepatide significantly reduced the composite risk of cardiovascular death or worsening heart failure and improved health status compared to placebo, though it was associated with higher gastrointestinal side effects. For summary, click here . Packer M, Zile MR, Kramer CM, et al. (2024). “Tirzepatide for Heart...

In patients with type 2 diabetes , intensive blood-pressure control (targeting systolic BP

This episode explores the potential of semaglutide, a once-weekly GLP-1 analog, in managing type 2 diabetes. We examines a groundbreaking study published in Diabetes Care which found that semaglutide effectively reduces HbA1c levels and promotes weight loss in patients. The episode breaks down the study's findings, highlighting the dose-dependent effects of semaglutide and strategies for managing...